Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Richard A. Heyman offered 518 shares of the agency’s inventory in a transaction dated Tuesday, October 1st. The inventory was offered at a median worth of $27.54, for a complete worth of $14,265.72. Following the sale, the director now instantly owns 128,585 shares within the firm, valued at roughly $3,541,230.90. The sale was disclosed in a doc filed with the SEC, which is accessible by means of this hyperlink.
Enliven Therapeutics Buying and selling Up 0.8 %
Shares of ELVN traded up $0.21 throughout mid-day buying and selling on Thursday, hitting $25.51. The corporate’s inventory had a buying and selling quantity of 308,043 shares, in comparison with its common quantity of 262,300. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year excessive of $27.67. The agency has a market capitalization of $1.20 billion, a P/E ratio of -12.82 and a beta of 1.09. The agency has a 50-day easy transferring common of $23.19 and a 200 day easy transferring common of $21.84.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) final issued its earnings outcomes on Tuesday, August thirteenth. The corporate reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a bunch, sell-side analysts predict that Enliven Therapeutics, Inc. will publish -1.98 EPS for the present fiscal 12 months.
Institutional Buyers Weigh In On Enliven Therapeutics
A lot of hedge funds and different institutional traders have not too long ago modified their holdings of the inventory. Quest Companions LLC raised its stake in shares of Enliven Therapeutics by 87.3% through the 2nd quarter. Quest Companions LLC now owns 1,592 shares of the corporate’s inventory value $37,000 after shopping for a further 742 shares over the past quarter. China Common Asset Administration Co. Ltd. elevated its holdings in Enliven Therapeutics by 67.0% through the 1st quarter. China Common Asset Administration Co. Ltd. now owns 7,952 shares of the corporate’s inventory valued at $140,000 after buying a further 3,189 shares within the final quarter. EntryPoint Capital LLC acquired a brand new place in Enliven Therapeutics through the first quarter value about $167,000. SG Americas Securities LLC acquired a brand new place in Enliven Therapeutics through the third quarter value about $256,000. Lastly, The Producers Life Insurance coverage Firm bought a brand new stake in shares of Enliven Therapeutics within the second quarter valued at about $322,000. 95.08% of the inventory is at the moment owned by institutional traders and hedge funds.
Wall Avenue Analyst Weigh In
A lot of equities analysis analysts not too long ago weighed in on ELVN shares. Robert W. Baird started protection on shares of Enliven Therapeutics in a analysis report on Tuesday, June eleventh. They issued an “outperform” ranking and a $32.00 worth goal for the corporate. Baird R W raised Enliven Therapeutics to a “strong-buy” ranking in a analysis report on Tuesday, June eleventh. Lastly, HC Wainwright restated a “purchase” ranking and set a $37.00 worth goal on shares of Enliven Therapeutics in a analysis report on Tuesday.
Learn Our Newest Inventory Evaluation on ELVN
Enliven Therapeutics Firm Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical firm, focuses on the invention and improvement of small molecule inhibitors to assist sufferers with most cancers. The corporate’s lead product candidates comprise ELVN-001, which is being evaluated in a Section 1 scientific trial in adults with continual myeloid leukemia; and ELVN-002, a Section 1 scientific trial in adults with stable tumors with HER2 alterations.
See Additionally
Obtain Information & Scores for Enliven Therapeutics Every day – Enter your e-mail deal with under to obtain a concise each day abstract of the newest information and analysts’ scores for Enliven Therapeutics and associated corporations with MarketBeat.com’s FREE each day e-mail e-newsletter.